Comparative Effects of A2 Platinum Stage 1 Infant Formula on Infant Digestion and Comfort

NCT ID: NCT04733937

Last Updated: 2024-10-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 180 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-07-07
• Study Completion Date: 2022-04-16

Brief Summary

This trial is a single-blind, randomized, controlled, parallel-designed trial to compare the effects of a2 Platinum® stage 1 infant formula versus conventional, A1 and A2 β-casein-containing stage 1 infant formula versus breastfeeding on crying, tolerance, gut health, and immune function.

Detailed Description

The protocol was updated from V8.2 to V9.1 and was approved by the Ethical Committee of Shanghai First Maternity and Infant Hospital, the main site. The major changes are: from "blind to participants" to "non-blind to participants"; from "Single-Centre" to "Multi-Centre"; number of subjects from "270" to "180"; trial period from "3 weeks" to "4 weeks"; and number of visits from "6" to "4".

Conditions

Healthy Infants

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: SUPPORTIVE_CARE
• Blinding Strategy: TRIPLE

Study Groups

a2 Group

The infant group consuming a2 Platinum® stage 1 infant formula

Group Type: ACTIVE_COMPARATOR

a2 Platinum® stage 1 infant formula

Intervention Type: OTHER

Upon randomization (if not included in the breastfed group), each participant will be provided with up to 105 days' supply of the standardized formula and up to 28 days' supply of the allocated formula. Participants and study investigators will conduct the trial via a pre-determined randomization schedule.

Control Group

The infant group consuming conventional, A1 and A2 β-casein containing stage 1 infant formula

Group Type: ACTIVE_COMPARATOR

Conventional, A1 and A2 β-casein containing stage 1 infant formula

Intervention Type: OTHER

Upon randomization (if not included in the breastfed group), each participant will be provided with up to 105 days' supply of the standardized formula and up to 28 days' supply of the allocated formula. Participants and study investigators will conduct the trial via a pre-determined randomization schedule.

breast feeding

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

a2 Platinum® stage 1 infant formula

Upon randomization (if not included in the breastfed group), each participant will be provided with up to 105 days' supply of the standardized formula and up to 28 days' supply of the allocated formula. Participants and study investigators will conduct the trial via a pre-determined randomization schedule.

Intervention Type: OTHER

Conventional, A1 and A2 β-casein containing stage 1 infant formula

Upon randomization (if not included in the breastfed group), each participant will be provided with up to 105 days' supply of the standardized formula and up to 28 days' supply of the allocated formula. Participants and study investigators will conduct the trial via a pre-determined randomization schedule.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. 0-76 days of age after birth, inclusive (day of birth is considered day 0)

2. Singleton birth

3. Gestational age of 37-42 weeks (36 weeks and six days is considered 36 weeks gestational age)

4. Birth weight of 2,500 g to 4,500 g

5. Signed informed consent obtained for infant's participation in the survey

6. Parent or guardian of infant agrees not to enrol infant in another interventional clinical survey while participating in this survey

7. Parent or guardian agrees to formula-feed the baby as per the randomization schedule

For the formula-fed groups, participants in addition to the above-listed criteria, must also meet the following criterion:

• Parent or guardian agrees that the baby will be fed with standardized formula upon enrolment and switched to randomized formula at baseline (90-105 days of age)

For the breastfed group, participants in addition to the above-listed criteria, must also meet the following criterion:

• Parent or guardian agrees that the baby will be breast-fed

Exclusion Criteria

1. Infant with inborn malformation and with hereditary and/or chronic and/or inborn diseases that could interfere with the survey (e.g. being unable to breast-feed or formula-fed)

2. Diseases jeopardizing intrauterine growth

3. Known or increased risk of IgE-mediated cow's milk protein allergy

1. (i.e. one of the biological parents and/or siblings diagnosed with similar allergy,

2. asthma, hay fever, etc.)

4. Infant with an acute infection or gastroenteritis at time of randomization

5. Evidence of feeding difficulties or formula intolerance, such as vomiting or poor intake at time of randomization

6. Participation in another clinical trial

7. Investigator's uncertainty about the willingness or ability of the parents to comply with the protocol requirements (including to fill in the diaries and to wait with introducing weaning foods until 4 months of age, and capability and willingness to do stool sample collection, handling, processing, and storage as instructed)

8. Infant is immunocompromised (according to a doctor's diagnosis of immunodeficiencies such as combined immunodeficiencies, DiGeorge Syndrome, Wiskott-Aldrich syndrome, severe congenital neutropenia and secondary immunodeficiencies linked to HIV infection, Down Syndrome or others) and children with known head/brain disease/injury such as microcephaly, macrocephaly or others

Exit Criteria:

1. Ineligibility (either arising during the trial or retrospectively having been overlooked at screening)

2. Significant protocol deviation

3. Significant non-compliance with product regimen or trial requirements

4. An adverse event (including one occurring before the start of the trial period) which requires discontinuation of the trial product or results in inability to continue to comply with trial procedures

5. Disease progression which requires discontinuation of the trial product or results in inability to continue to comply with trial procedures

6. Withdrawal of Consent

7. Lost to follow up

8. Weight at Visit 2 is <95% of birth weight [(weight at Visit 2÷birth weight) x 100 <95%]

9. Use of antibiotics, steroids or prebiotics/probiotics anytime between 14 days before baseline and trial completion

10. Participant whose mother has used any form of antibiotics or steroids while breastfeeding

11. More than 1 feed of formula milk per day for the breastfed group

12. More than 2 feeds of breast milk per day for the formula groups

• Minimum Eligible Age: 0 Days
• Maximum Eligible Age: 76 Days
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Shanghai First Maternity and Infant Hospital

OTHER

Sponsor Role: collaborator

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

Sponsor Role: collaborator

Edanz Group Japan Ltd

UNKNOWN

Sponsor Role: collaborator

Women & Children's Health Care Hospital of Linyi, China

UNKNOWN

Sponsor Role: collaborator

Beijing Esmile Technology Co. Ltd.

UNKNOWN

Sponsor Role: collaborator

Nanjing Maternity and Child Health Care Hospital

OTHER

Sponsor Role: collaborator

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

OTHER

Sponsor Role: collaborator

Second Hospital of Jilin University

OTHER

Sponsor Role: collaborator

a2 Milk Company Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jiangqin Liu, MD

Role: PRINCIPAL_INVESTIGATOR

Shanghai First Maternity and Infant Hospital

Locations

Nanjing Maternity and Child Health Care Hospital

Nanjing, Jiangsu, China

Second Hospital of Jilin University

Changchun, Jilin, China

Women & Children's Health Care Hospital of Linyi, China

Linyi, Shandong, China

Shanghai First Maternity and Infant Hospital

Shanghai, Shanghai Municipality, China

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

Tianjin, Tianjin Municipality, China

Countries

China

Other Identifiers

A2MC-G190549140

Identifier Type: -

Identifier Source: org_study_id